|
Myocardial Infarction
|
0.230 |
Biomarker
|
disease |
BEFREE |
Recently, CTSB has been linked to myocardial infarction.
|
25713304 |
2015 |
|
Myocardial Infarction
|
0.230 |
Biomarker
|
disease |
BEFREE |
[Retracted] Cathepsin B inhibition attenuates cardiac dysfunction and remodeling following myocardial infarction by inhibiting the NLRP3 pathway.
|
28944892 |
2017 |
|
Myocardial Infarction
|
0.230 |
Biomarker
|
disease |
BEFREE |
Cathepsin B is a prominent lysosomal protease and is involved in apoptosis as well as degradation of myofibrillar proteins in myocardial infarction.
|
16480925 |
2006 |
|
Liver carcinoma
|
0.230 |
GeneticVariation
|
disease |
BEFREE |
The association between CTSB C76G SNP and greater tumor size may warrant further study in regards to the biology of HCC.
|
25106406 |
2014 |
|
Liver carcinoma
|
0.230 |
AlteredExpression
|
disease |
BEFREE |
SerpinB3 (SB3) is a hypoxia and hypoxia-inducible factor (HIF)-2α-dependent cysteine-protease inhibitor up-regulated in hepatocellular carcinoma (HCC), released by cancer cells and able to stimulate proliferation and epithelial-to-mesenchymal-transition.
|
31817100 |
2019 |
|
Liver carcinoma
|
0.230 |
Biomarker
|
disease |
BEFREE |
Integrin αvβ3 is required for cathepsin B-induced hepatocellular carcinoma progression.
|
25572981 |
2015 |
|
Intracranial Aneurysm
|
0.210 |
GeneticVariation
|
disease |
BEFREE |
The mRNA level of collagen 1A2 (COL1A2), tissue inhibitor of metalloproteinase 4 (TIMP4), and cathepsin B (CTSB) genes were studied in 23 aneurysmal walls and 19 superficial temporal arteries harvested from 23 patients undergoing clipping of IAs, by real-time polymerase chain reaction method.
|
27381111 |
2018 |
|
Fatty Liver
|
0.210 |
Biomarker
|
disease |
BEFREE |
Proteomic analysis coupled with a bioinformatics-driven approach revealed that these mice express greater amounts of hepatic cathepsin B and lower amounts of liver fatty acid-binding protein (LFABP) than their wildtype littermates. siRNA-mediated knockdown of cathepsin B in McA-RH7777 cells resulted in a 39% increase in [<sup>3</sup>H]TAG associated with VLDL secretion.
|
29259130 |
2018 |
|
Liver neoplasms
|
0.210 |
AlteredExpression
|
group |
BEFREE |
Relative amounts of mRNA for cathepsin B were measured in normal murine liver and three murine tumors, an invasive liver tumor (hepatoma, Hepa cl 9) and two melanoma variants (B16-F1 and B16 amelanotic melanoma, B16a).
|
2924910 |
1989 |
|
Malignant neoplasm of liver
|
0.210 |
AlteredExpression
|
disease |
BEFREE |
Here, we found that ADCX, a natural cycloartane triterpenoid extracted from the traditional Chinese medicine (TCM) source Cimicifugae rhizoma (Shengma), impaired autophagic degradation by suppressing lysosomal cathepsin B (CTSB) expression in multidrug-resistant liver cancer HepG2/ADM cells, thereby leading to autophagic flux inhibition.
|
29074104 |
2017 |
|
Parkinson Disease
|
0.140 |
Biomarker
|
disease |
BEFREE |
Two of the reported risk loci, ANK2/CAMK2D and CTSB, were non-polymorphic in East Asians and therefore not implicated in PD risk in the East Asian population.
|
30814023 |
2020 |
|
Parkinson Disease
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson's Disease.
|
30450037 |
2018 |
|
Parkinson Disease
|
0.140 |
Biomarker
|
disease |
BEFREE |
Mutations the in human DJ-1 (hDJ-1) gene are associated with early-onset autosomal recessive forms of Parkinson's disease (PD). hDJ-1/parkinsonism associated deglycase (PARK7) is a cytoprotective multi-functional protein that contains a conserved cysteine-protease domain.
|
27556455 |
2016 |
|
Parkinson Disease
|
0.140 |
Biomarker
|
disease |
BEFREE |
Analysis of other lysosomal enzymes revealed a significant decrease in activity for the lysosomal aspartic acid protease cathepsin D but not for glucocerebrosidase (GCase) or cathepsin B in late-stage PD temporal cortex.
|
29196214 |
2018 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cathepsin B plays a critical role in inducing Alzheimer's disease-like phenotypes following chronic systemic exposure to lipopolysaccharide from Porphyromonas gingivalis in mice.
|
28610747 |
2017 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Significantly, inhibitors of cathepsin B improved memory, with reduced amyloid plaques and decreased Abeta(40/42) in brains of AD animal models expressing amyloid precursor protein containing the WT beta-secretase site.
|
18979625 |
2008 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further investigation of cathepsin B as a predictor of AD is warranted.
|
20930303 |
2010 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data illustrate the role of CatB in producing pGlu-Aβ and flAβ that participate as key factors in the development of AD.
|
24595198 |
2014 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence.
|
22337825 |
2012 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein.
|
18184658 |
2008 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
As for Alzheimer's disease (AD) related pathology, chia seed not only increased α-secretase such as ADAM10 and insulin degrading enzyme (IDE), but also increased β-secretase including beta-secretase 1 (BACE1) and cathepsin B, with an overall effects of elevation in the hippocampal Aβ<sub>42</sub> level; chia seed slightly reduced p-Tauser404 in the hippocampus; while an elevation in neuro-inflammation with the activation of glial fibrillary acidic protein (GFAP) and Ibα-1 were observed post chia seed supplementation.
|
30110883 |
2018 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results support the idea that CatB can speed Aß metabolism through lysosomal pathways and as such reduce AD-associated memory deficits.
|
27966067 |
2017 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that cathepsin B plays novel roles in the metabolism of APP and that an inhibition of APP phosphorylation is an attractive therapeutic target for Alzheimer's disease.
|
21746863 |
2011 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that the specific inhibition of microglial cathepsin B may lead to neuroprotective outcomes in AD, while the functions of this cysteine protease in neurons appears to be very complex and further studies are required to fully elucidate the pathophysiological role of neuronal cathepsin B.
|
29454581 |
2018 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The specificity of cathepsin B to cleave the WT beta-secretase site, but not the Swe mutant site, of APP for Abeta production explains the distinct inhibitor responses in the different AD mouse models.
|
20536395 |
2010 |